Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program
- PMID: 21704447
- DOI: 10.1016/j.eururo.2011.06.027
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program
Abstract
Background: Active surveillance (AS) protocols for low-risk prostate cancer (PCa) generally include repeat prostate biopsies at predefined follow-up intervals.
Objective: To study the outcome of routinely obtained 1-yr repeat biopsies and factors predicting reclassification to higher risk, to contribute to risk stratification for men on AS.
Design, setting, and participants: We analysed men with low-risk PCa (clinical stage ≤ T2, prostate-specific antigen (PSA) ≤ 10 ng/ml, PSA density <0.2 ng/ml per millilitre, one or two positive biopsy cores, and Gleason score ≤ 6) who had been included in a prospective AS protocol.
Interventions: PSA was measured 3-monthly and the first volume-dependent repeat biopsy was scheduled 1 yr after diagnosis, independent of PSA doubling time (PSA-DT). Reclassification to higher risk disease on repeat biopsy was defined as Gleason score ≥ 7 or ≥ 3 positive cores.
Measurements: We analysed whether baseline patient characteristics and PSA-DT were associated with reclassification to more aggressive PCa on repeat biopsy.
Results and limitations: A first repeat biopsy was taken in 757 patients after median follow-up of 1.03 yr. The results of repeat biopsies were favourable (no or low-risk PCa) in 594 patients (78.5%) and led to reclassification of risk in 163 (21.5%). Analysis showed that reclassification to higher risk was significantly influenced by the number of initial positive cores (two vs one) (odds ratio [OR]: 1.8; p=0.002) and higher PSA density (OR: 2.1; p=0.003). The outcome was not significantly influenced by age, clinical stage, total number of biopsy cores, or PSA. Adding PSA-DT at time of repeat biopsy to the model showed PSA-DT <3 yr to be significantly associated with reclassification to higher risk (OR: 1.7; p=0.015). Data on tumour involvement per biopsy core were not available.
Conclusions: Clinical features at baseline and during follow-up in our AS cohort are significantly associated with short-term reclassification to higher risk on repeat biopsy. These characteristics can potentially be used for risk stratification of men with PCa who are apparently at favourable risk.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.Eur Urol. 2013 Apr;63(4):597-603. doi: 10.1016/j.eururo.2012.11.005. Epub 2012 Nov 12. Eur Urol. 2013. PMID: 23159452 Clinical Trial.
-
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.Eur Urol. 2012 Aug;62(2):195-200. doi: 10.1016/j.eururo.2012.02.002. Epub 2012 Feb 14. Eur Urol. 2012. PMID: 22342775
-
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5. Eur Urol. 2011. PMID: 21482022
-
Prostate biopsy: who, how and when. An update.Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Can J Urol. 2005. PMID: 15780165 Review.
-
Active surveillance: the Canadian experience.Curr Opin Urol. 2012 May;22(3):222-30. doi: 10.1097/MOU.0b013e328352598c. Curr Opin Urol. 2012. PMID: 22453335 Review.
Cited by
-
Active surveillance for prostate cancer.Int J Urol. 2016 Mar;23(3):211-8. doi: 10.1111/iju.13016. Epub 2015 Nov 30. Int J Urol. 2016. PMID: 26621054 Free PMC article.
-
Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.World J Urol. 2016 Feb;34(2):253-60. doi: 10.1007/s00345-015-1628-y. Epub 2015 Jul 10. World J Urol. 2016. PMID: 26160006 Free PMC article. Clinical Trial.
-
Eleven-year management of prostate cancer patients on active surveillance: what have we learned?Tumori. 2017 Sep 18;103(5):464-474. doi: 10.5301/tj.5000649. Epub 2017 Jun 14. Tumori. 2017. PMID: 28623636 Free PMC article.
-
Our results of active surveillance for localized prostate cancer patients.Turk J Urol. 2013 Mar;39(1):1-5. doi: 10.5152/tud.2013.001. Turk J Urol. 2013. PMID: 26328069 Free PMC article.
-
Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.Eur Urol. 2015 Apr;67(4):619-26. doi: 10.1016/j.eururo.2014.10.010. Epub 2014 Oct 31. Eur Urol. 2015. PMID: 25457014 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous